Sign in with Google
bearish
Standing Alone in the Ampakines Pipeline: Biogen Sees Potential in Pfizer's Neuropsychiatry Asset
271 Views15 Mar 2018 14:36
On 12 March 2018, Biogen Inc (BIIB US) announced an agreement to acquire Pfizer Inc (PFE US)'s first-in-class, Phase 2b ready AMPA receptor...
SUMMARY
(Sign Up to Access)Full Insight
(Paid Plans Only, 3-minute read)
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- [Quiddity Index] MV Global Defense Jun25 Rebalance Results: Flow Expectations
- Bank of Japan's June Policy Decision: A Non-Event for Markets?
- MV Global Defense Industry Index Rebalance: US$1.1bn Round-Trip Trade as Stocks Soar
- MV Global Uranium & Nuclear Energy/Infra Index Rebalance: Double Inclusion for CGN Mining
- A/H Premium Tracker (To 13 June 2025): HUGE H-Share Outperf Across The Board, "Beautiful Skew Move"
Top Unpaywalled Insights
More »- HK Connect SOUTHBOUND Flows (To 13 June 2025); Volumes Up, TECH Down, HEALTHCARE Bought Big
- [IO Technicals 2025/24] Downward Momentum Lingers
- China A-Share Consumer Staples: An Analysis of the Opportunities Ahead
- Bearishness Persist in Soybeans Despite Rebound Hopes
- Curator's Cut: The Next Labubu, Crypto Equities and Tracking APAC Buybacks
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Standing Alone in the Ampakines Pipeline: Biogen Sees Potential in Pfizer's Neuropsychiatry Asset15 Mar 2018
- Will Actinogen Ace Alzheimer's?01 Mar 2018
- Acadia Pharma: Hedge Fund Favorite and Upcoming Catalyst.08 Dec 2016
- Some Actionable Ideas in the Biotechnology and Pharmaceutical Sector: October 31 Sector Update01 Nov 2016
x